Please login to the form below

Not currently logged in
Email:
Password:

IL-13 inhibitor

This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Drugs like Fasenra and GlaxoSmithKline’s rival IL-5 inhibitor Nucala (mepolizumab) have emerged as an important treatment option for people with severe asthma characterised by high levels of eosinophils. ... Regeneron’s new candidate Dupixent

Latest news

  • GSK sells eczema and psoriasis drug to Dermavant for £250m GSK sells eczema and psoriasis drug to Dermavant for £250m

    The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme. ... Meanwhile, in atopic dermatitis, Regeneron and Sanofi’s IL4/IL-13 inhibitor Dupixent (dupilumab)

  • AZ’s Fasenra hit by COPD trial failure AZ’s Fasenra hit by COPD trial failure

    Nucala was the first IL-5 inhibitor to reach the market in 2015, and made £344m ($465m) in sales last year. ... IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic

  • NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

    Despite the confidential discount on Dupixent’s list price of £1, 264.89 per pack of two syringes of the IL-4 and IL-13 inhibitor - developed with Regeneron - the cost

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    AstraZeneca has picked up an approval in the EU for its interleukin-5 inhibitor Fasenra in severe asthma, mirroring its US approval in this indication last November. ... Prospects for IL-13 inhibitor tralokinumab look terminal after three failed

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    The US FDA has approved AstraZeneca’s interleukin-5 inhibitor Fasenra for severe asthma, setting up a fight in the market with rival drugs from GlaxoSmithKline and Teva. ... Prospects for IL-13 inhibitor tralokinumab look rocky after two failed

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics